CIK 0000875320
- Large accelerated filer
VERTEX PHARMACEUTICALS INC / MA
Sign in to watch- Ticker
- VRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- Operating
- EIN
- 043039129
- Phone
- +1 617-341-6393
- Business address
- 50 NORTHERN AVENUE, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,307,135
- in 1 filing, $6.3M under 10b5-1 plans
Net −$6,307,135. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-10-15 | Upadhyay Suketu Director | Grant or award · Deferred Stock Units | +86.83 | $410.31 | $36K | 2,638.33 |
| 2025-10-15 | SACHS BRUCE I Director | Grant or award · Deferred Stock Units | +115.77 | $410.31 | $47K | 15,457.43 |
| 2025-10-02 | Biller Jonathan EVP and Chief Legal Officer | Sale 10b5-1 | −694 | $404.21 | $281K | 15,653 |
| 2025-10-01 | Biller Jonathan EVP and Chief Legal Officer | Shares withheld for taxes 10b5-1 | −1,259 | $400.00 | $504K | 16,347 |
| 2025-08-27 | Bhatia Sangeeta N. Director | Sale 10b5-1 | −266 | $386.69 | $103K | 4,565 |
| 2025-08-06 | Kewalramani Reshma CEO & President | Purchase | +4,290 | $389.08 | $1.7M | 110,258 |
| 2025-08-06 | Kewalramani Reshma CEO & President | Purchase | +5,710 | $389.95 | $2.2M | 115,968 |
| 2025-08-06 | SACHS BRUCE I Director | Purchase | +1,634 | $389.36 | $636K | 41,634 |
| 2025-08-06 | SACHS BRUCE I Director | Purchase | +3,366 | $389.84 | $1.3M | 45,000 |
| 2025-07-15 | Upadhyay Suketu Director | Grant or award · Deferred Stock Units | +75.9 | $469.34 | $36K | 2,551.51 |
| 2025-07-15 | SACHS BRUCE I Director | Grant or award · Deferred Stock Units | +101.21 | $469.34 | $48K | 15,341.67 |
| 2025-07-01 | Arbuckle Stuart A EVP, COO | Shares withheld for taxes | −37,243 | $450.23 | $16.8M | 63,368 |
| 2025-05-15 | ALTSHULER DAVID EVP, Chief Scientific Officer | Sale 10b5-1 | −52 | $424.69 | $22K | 23,281 |
| 2025-05-13 | Arbuckle Stuart A EVP, COO | Grant or award | +37,622 | 100,611 | ||
| 2025-05-02 | Bhatia Sangeeta N. Director | Sale 10b5-1 | −400 | $505.86 | $202K | 4,831 |
| 2025-05-01 | Upadhyay Suketu Director | Grant or award | +796 | 3,355 | ||
| 2025-05-01 | Upadhyay Suketu Director | Returned to the company | −1,001 | 2,354 | ||
| 2025-05-01 | Upadhyay Suketu Director | Grant or award · Deferred Stock Units | +1,001 | 2,475.6 | ||
| 2025-05-01 | Thornberry Nancy Director | Grant or award | +398 | 2,035 | ||
| 2025-05-01 | Thornberry Nancy Director | Grant or award · Stock Option (Right to Buy) | +1,199 | 1,199 |
Page 12 of 18 · 344 trades